null

null

null

null

null

null

null

null

null

null

null

null

null

null

0.50x Total Debt / Equity (Conservative)

Roughly 30% of debt is floating-rate; 20% rate increase pressures free cash flow by ~$50-60M annually, limiting buyback capacity.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Semiconductor components sourced via Asia (Taiwan/South Korea) and specialized optical/detection materials dependent on Chinese rare-earth supply chains.

EUR (~40% of international revenue), GBP, and CNY exposure; EUR/USD 10% devaluation would compress international revenue by ~$80-100M annually.

US ~70% of revenue; Europe ~20%; Asia-Pacific ~8%; currency devaluation in EUR and GBP poses greatest sovereign FX risk.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs publicly; sole-source suppliers exist for specialized mammography detector components — moderate lock-in risk.

Hologic operates on-premise and hybrid infrastructure for diagnostic systems; cloud disruption would affect data analytics/software but not core device revenue.

Recurring reagent and consumable revenue (~60%) is device-dependent, not cloud-dependent; SaaS-layer disruption would be a minor operational inconvenience.

High API/system coupling in laboratory information systems (LIS) integrations; hospital customers face 12-24 month switching timelines, creating strong retention moat.

Revenue model is product/service sales and reagent subscriptions — no Howey Test applicability; zero securities-law revenue risk from this lens.

Very High

Processes patient diagnostic data across EU and US; GDPR Article 9 (health data) and CCPA exposure significant; requires ongoing DPA agreements and localization.

Dominant ~70% US mammography market share flagged by regulators historically; potential scrutiny on bundled reagent contracts (razor/blade model) in molecular diagnostics.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~60-65% recurring (reagents, service contracts, software subscriptions); ~35-40% transactional (capital equipment sales); highly recurring for a medtech company.

Razor-and-blade: instruments placed, recurring high-margin consumables/reagents monetize volume; supplemented by multi-year service contracts and software licenses.

Proprietary closed-system cartridges enable premium pricing; hospital budget pressure and GPO contracts cap upside; gross margins ~63-65% reflect durable pricing power.

Strong — FDA-cleared monopoly positions in mammography and molecular STI testing allow 3-5% annual price increases above medical inflation.

51.6% Gross Margin (Strong (40-60%))

Minimal free-rider risk; closed proprietary systems lock reagent purchases to Hologic instruments — competitors cannot access installed base without full system replacement.

Revenue growth is sublinear to headcount; consumable/reagent volume scales with installed base requiring minimal incremental headcount — high operating leverage model.

Marginal cost of incremental reagent revenue is low (~30-35% COGS); doubling molecular diagnostics revenue would require <20% headcount increase.

null

At 10x scale, CAC efficiency improves as installed base network effects reduce sales cycle; however, hospital consolidation limits total addressable accounts.

Weak direct network effects; strong indirect effects via installed base creating data/AI training advantages in imaging AI and diagnostics algorithms.

7.6% Return on Assets (Excellent)

Tier 1 recession resistant; cancer screening and STI testing are non-discretionary clinical necessities; COVID pulled forward demand, but baseline is highly defensive.

Hospitals and health systems (~55% of revenue); no single customer >5% of revenue; GPO concentration (Vizient, Premier) poses indirect negotiation risk.

Independent diagnostic labs and women's health clinics (~30%); government/public health agencies (~10%) particularly for molecular diagnostics.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

1.4% CapEx / Revenue (Low-CapEx Asset-Light)

0000859737

HOLX — trading at ~15-17x forward earnings, modest discount to medtech peers; commodity/regulatory risk is real but priced in; not deeply discounted on combined risk basis.